# CSL LTD

Summary updated: 2026-09-28T14:16:49.065091Z
Canonical: https://finbar.com/research/companies/csl

## Overview

CSL Limited is an Australian biotechnology company headquartered in Melbourne. Founded in 1916, it develops and supplies medicines and vaccines for serious and complex diseases. Its mission centres on saving lives and addressing areas of high unmet medical need. [1](https://www.csl.com/we-are-csl/worldwide-locations)[2](https://www.csl.com/we-are-csl)[3](https://app.finbar.com/go?id=P167757116)[4](https://app.finbar.com/go?id=P167757057)

CSL operates through three principal businesses: CSL Behring, which provides therapies for rare and serious conditions; CSL Seqirus, which focuses on influenza vaccines and pandemic preparedness; and CSL Vifor, which specialises in iron deficiency and nephrology. Its products reach patients in more than 100 countries. In fiscal 2025, CSL reported approximately US$15.6 billion in revenue and employed more than 29,000 people globally. [5](https://app.finbar.com/go?id=P167757131)[6](https://app.finbar.com/go?id=P167757134)[7](https://app.finbar.com/go?id=P167757137)[8](https://app.finbar.com/go?id=P167757066)[9](https://app.finbar.com/go?id=P167757065)[10](https://app.finbar.com/go?id=P167757067)
[3](https://app.finbar.com/go?id=P167757116)[4](https://app.finbar.com/go?id=P167757057)[5](https://app.finbar.com/go?id=P167757131)[6](https://app.finbar.com/go?id=P167757134)[7](https://app.finbar.com/go?id=P167757137)[8](https://app.finbar.com/go?id=P167757066)[9](https://app.finbar.com/go?id=P167757065)[10](https://app.finbar.com/go?id=P167757067)[1](https://www.csl.com/we-are-csl/worldwide-locations)[2](https://www.csl.com/we-are-csl)

## Products & services

CSL Behring produces plasma-derived and recombinant medicines. Its immunoglobulin products include Hizentra, a 20% subcutaneous therapy, and Privigen, a 10% intravenous therapy; they are used for immune disorders, with indications varying by market. Its portfolio also includes the albumin product Albumex, the haemophilia treatments Idelvion and Afstyla, Hemgenix gene therapy for eligible adults with haemophilia B, and the hereditary-angioedema treatments Haegarda and Berinert. CSL Plasma collects donor plasma for the manufacture of plasma-derived therapies. Immunoglobulins generated US$6.06 billion in revenue in fiscal 2025, approximately 54% of CSL Behring’s segment revenue. [11](https://app.finbar.com/go?id=P167752452)[12](https://app.finbar.com/go?id=P167752455)[13](https://app.finbar.com/go?id=P167757449)[14](https://www.csl.com/we-are-csl/our-businesses-and-products/csl-behring/csl-plasma)[15](https://app.finbar.com/go?id=T19580735)[16](https://app.finbar.com/go?id=T19580731)

CSL Seqirus makes seasonal influenza vaccines, including the adjuvanted Fluad, cell-based Flucelvax and Afluria. It also supplies pandemic and pre-pandemic influenza products and receives pandemic-reservation fees. Adjuvanted egg-based vaccines accounted for US$901 million of its fiscal 2025 revenue. [17](https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-products)[18](https://app.finbar.com/go?id=P167752456)[15](https://app.finbar.com/go?id=T19580735)

CSL Vifor’s products focus on iron deficiency and kidney disease. They include the intravenous iron therapy Ferinject, the phosphate binder Velphoro for patients with chronic kidney disease, and Veltassa for hyperkalaemia. Its iron product category generated US$1.03 billion in fiscal 2025, approximately 46% of CSL Vifor’s segment revenue. The company also offers product-specific patient support and, for certain investigational medicines, managed-access programs. [19](https://app.finbar.com/go?id=P167757377)[20](https://app.finbar.com/go?id=T19580682)[15](https://app.finbar.com/go?id=T19580735)[16](https://app.finbar.com/go?id=T19580731)[21](https://www.csl.com/patients-public-health/patient-support-and-organizations)[22](https://www.csl.com/patients-public-health/patient-support-and-organizations/csl-vifor-managed-access-programs)
[11](https://app.finbar.com/go?id=P167752452)[12](https://app.finbar.com/go?id=P167752455)[13](https://app.finbar.com/go?id=P167757449)[15](https://app.finbar.com/go?id=T19580735)[16](https://app.finbar.com/go?id=T19580731)[18](https://app.finbar.com/go?id=P167752456)[15](https://app.finbar.com/go?id=T19580735)[19](https://app.finbar.com/go?id=P167757377)[20](https://app.finbar.com/go?id=T19580682)[15](https://app.finbar.com/go?id=T19580735)[16](https://app.finbar.com/go?id=T19580731)[23](https://www.csl.com/we-are-csl/our-businesses-and-products/csl-plasma)[17](https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-products)[21](https://www.csl.com/patients-public-health/patient-support-and-organizations)[22](https://www.csl.com/patients-public-health/patient-support-and-organizations/csl-vifor-managed-access-programs)

## Geographic presence

CSL is headquartered in Melbourne, Australia, and sells products in more than 100 countries. In the year ended 30 June 2025, it reported US$15.56 billion in revenue across its geographic areas of operation: the United States accounted for US$7.31 billion (47.0%), followed by the rest of the world at US$4.45 billion (28.6%), Germany at US$947 million (6.1%), Australia at US$890 million (5.7%), China and Hong Kong at US$849 million (5.5%), the United Kingdom at US$807 million (5.2%), and Switzerland at US$302 million (1.9%). The report does not specify whether this breakdown assigns revenue by customer location or operating location. [24](https://www.csl.com/contact)[25](https://investors.csl.com/annualreport/2025/2/)[26](https://investors.csl.com/annualreport/2025/101/)

CSL’s manufacturing sites are in Australia (Parkville, Tullamarine and Broadmeadows), the United States (Holly Springs and Kankakee), Switzerland (Bern and St. Gallen), the United Kingdom (Liverpool) and Germany (Marburg). Its plasma-collection network operates in the United States and Europe. [27](https://investors.csl.com/annualreport/2025/21/)[25](https://investors.csl.com/annualreport/2025/2/)
[28](https://app.finbar.com/go?id=T19580734)[28](https://app.finbar.com/go?id=T19580734)[28](https://app.finbar.com/go?id=T19580734)[28](https://app.finbar.com/go?id=T19580734)[28](https://app.finbar.com/go?id=T19580734)[28](https://app.finbar.com/go?id=T19580734)[28](https://app.finbar.com/go?id=T19580734)[28](https://app.finbar.com/go?id=T19580734)[29](https://app.finbar.com/go?id=P167758623)[24](https://www.csl.com/contact)[25](https://investors.csl.com/annualreport/2025/2/)[26](https://investors.csl.com/annualreport/2025/101/)[27](https://investors.csl.com/annualreport/2025/21/)

## Business segments

CSL reports three operating segments. CSL Behring develops and supplies treatments for rare and serious diseases, principally plasma-derived therapies alongside recombinant medicines. CSL Seqirus is its influenza-vaccine business. CSL Vifor focuses on iron deficiency and nephrology treatments. These are the business units used to assess performance and allocate resources. [30](https://investors.csl.com/annualreport/2025/98/)[31](https://investors.csl.com/annualreport/2025/18/)[32](https://investors.csl.com/annualreport/2025/19/)[33](https://investors.csl.com/annualreport/2025/20/)

In fiscal 2025, CSL Behring generated approximately 72% of total segment revenue, CSL Seqirus 14%, and CSL Vifor 14%. CSL also breaks down revenue by product category within these businesses, but those categories are not separate operating segments. [34](https://investors.csl.com/annualreport/2025/99/)[35](https://investors.csl.com/annualreport/2025/102/)
[30](https://investors.csl.com/annualreport/2025/98/)[31](https://investors.csl.com/annualreport/2025/18/)[32](https://investors.csl.com/annualreport/2025/19/)[33](https://investors.csl.com/annualreport/2025/20/)[34](https://investors.csl.com/annualreport/2025/99/)[35](https://investors.csl.com/annualreport/2025/102/)

## Company history

CSL began in 1916 as the Australian government’s Commonwealth Serum Laboratories. Its early work included producing insulin for civilian use in 1923 and penicillin in 1944; it began producing the Salk polio vaccine in 1956. [36](https://www.eoas.info/bib-pdf/ASBS19098.pdf) The business was privatised and listed on the Australian Securities Exchange in 1994. [37](https://investors.csl.com/investors/shareholder-information/investor-faqs)

International acquisitions reshaped CSL in the following decades. It acquired the Swiss plasma-products business ZLB in 2000, then Aventis Behring in 2004, combining the two as ZLB Behring, the predecessor of CSL Behring. [38](https://investors.csl.com/annualreport/2025/7/)[39](https://investors.csl.com/PDF/afa5c02b-e24f-4dd0-b144-b352e8055d4f/CompletesacquisitionofAventisBehring) CSL expanded in influenza vaccines by acquiring Novartis’s influenza-vaccine business in 2015 and naming the combined business Seqirus. [40](https://www.cslseqirus.com.au/news/update-on-novartis-influenza-vaccines-acquisition) In 2022, it completed the acquisition of Vifor Pharma, adding the business that became CSL Vifor. [41](https://investors.csl.com/pdf/2214ff6d-26fb-48eb-90ab-3a1ec2f4e7d7/Completion-of-Vifor-Pharma-Acquisition.pdf?Platform=ListPage)
[36](https://www.eoas.info/bib-pdf/ASBS19098.pdf)[37](https://investors.csl.com/investors/shareholder-information/investor-faqs)[38](https://investors.csl.com/annualreport/2025/7/)[39](https://investors.csl.com/PDF/afa5c02b-e24f-4dd0-b144-b352e8055d4f/CompletesacquisitionofAventisBehring)[40](https://www.cslseqirus.com.au/news/update-on-novartis-influenza-vaccines-acquisition)[41](https://investors.csl.com/pdf/2214ff6d-26fb-48eb-90ab-3a1ec2f4e7d7/Completion-of-Vifor-Pharma-Acquisition.pdf?Platform=ListPage)

## Sources

1. [www.csl.com](https://www.csl.com/we-are-csl/worldwide-locations)
2. [www.csl.com](https://www.csl.com/we-are-csl)
3. [CSL LTD — Full financial report (2025 Y), p4](https://app.finbar.com/go?id=P167757116)
4. [CSL LTD — Full financial report (2025 Y), p2](https://app.finbar.com/go?id=P167757057)
5. [CSL LTD — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P167757131)
6. [CSL LTD — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P167757134)
7. [CSL LTD — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P167757137)
8. [CSL LTD — Full financial report (2025 Y), p3](https://app.finbar.com/go?id=P167757066)
9. [CSL LTD — Full financial report (2025 Y), p3](https://app.finbar.com/go?id=P167757065)
10. [CSL LTD — Full financial report (2025 Y), p3](https://app.finbar.com/go?id=P167757067)
11. [CSL LTD — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P167752452)
12. [CSL LTD — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P167752455)
13. [CSL LTD — Full financial report (2025 Y), p24](https://app.finbar.com/go?id=P167757449)
14. [www.csl.com](https://www.csl.com/we-are-csl/our-businesses-and-products/csl-behring/csl-plasma)
15. [CSL LTD — Full financial report (2025 Y), p102](https://app.finbar.com/go?id=T19580735)
16. [CSL LTD — Full financial report (2025 Y), p99](https://app.finbar.com/go?id=T19580731)
17. [www.csl.com](https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-products)
18. [CSL LTD — Full financial report (2024 Y), p26](https://app.finbar.com/go?id=P167752456)
19. [CSL LTD — Full financial report (2025 Y), p20](https://app.finbar.com/go?id=P167757377)
20. [CSL LTD — Full financial report (2025 Y), p25](https://app.finbar.com/go?id=T19580682)
21. [www.csl.com](https://www.csl.com/patients-public-health/patient-support-and-organizations)
22. [www.csl.com](https://www.csl.com/patients-public-health/patient-support-and-organizations/csl-vifor-managed-access-programs)
23. [www.csl.com](https://www.csl.com/we-are-csl/our-businesses-and-products/csl-plasma)
24. [www.csl.com](https://www.csl.com/contact)
25. [investors.csl.com](https://investors.csl.com/annualreport/2025/2/)
26. [investors.csl.com](https://investors.csl.com/annualreport/2025/101/)
27. [investors.csl.com](https://investors.csl.com/annualreport/2025/21/)
28. [CSL LTD — Full financial report (2025 Y), p101](https://app.finbar.com/go?id=T19580734)
29. [CSL LTD — Full financial report (2025 Y), p101](https://app.finbar.com/go?id=P167758623)
30. [investors.csl.com](https://investors.csl.com/annualreport/2025/98/)
31. [investors.csl.com](https://investors.csl.com/annualreport/2025/18/)
32. [investors.csl.com](https://investors.csl.com/annualreport/2025/19/)
33. [investors.csl.com](https://investors.csl.com/annualreport/2025/20/)
34. [investors.csl.com](https://investors.csl.com/annualreport/2025/99/)
35. [investors.csl.com](https://investors.csl.com/annualreport/2025/102/)
36. [www.eoas.info](https://www.eoas.info/bib-pdf/ASBS19098.pdf)
37. [investors.csl.com](https://investors.csl.com/investors/shareholder-information/investor-faqs)
38. [investors.csl.com](https://investors.csl.com/annualreport/2025/7/)
39. [investors.csl.com](https://investors.csl.com/PDF/afa5c02b-e24f-4dd0-b144-b352e8055d4f/CompletesacquisitionofAventisBehring)
40. [www.cslseqirus.com.au](https://www.cslseqirus.com.au/news/update-on-novartis-influenza-vaccines-acquisition)
41. [investors.csl.com](https://investors.csl.com/pdf/2214ff6d-26fb-48eb-90ab-3a1ec2f4e7d7/Completion-of-Vifor-Pharma-Acquisition.pdf?Platform=ListPage)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.